SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints

MT Newswires Live

2024/11/20

SAGE Therapeutics (SAGE) said Wednesday that its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.

The company said that the study was unable to demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo and as a result, it does not plan further development.

Sage Therapeutics' share price fell more than 8% in recent premarket activity on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2484920941"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484920941\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2484920941?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484920941","market":"fut","top_or_hot":-1,"title":"SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints","media":"MT Newswires Live","content":"<html><body><p> SAGE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SAGE) said Wednesday that its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.</p><p>The company said that the study was unable to demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo and as a result, it does not plan further development.</p><p><a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>' share price fell more than 8% in recent premarket activity on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-20 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SAGE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SAGE) said Wednesday that its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.</p><p>The company said that the study was unable to demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo and as a result, it does not plan further development.</p><p><a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a>' share price fell more than 8% in recent premarket activity on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAGE","symbol_name":"Sage Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484920941","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484920941","pubTimestamp":1732104150,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SAGE Therapeutics  said Wednesday that its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.The company said that the study was unable to demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo and as a result, it does not plan further development.Sage Therapeutics' share price fell more than 8% in recent premarket activity on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAGE":"Sage Therapeutics","BK4139":"生物科技"},"translate_title":"SAGE Therapeutics的Dalzanemdor研究未能达到主要和次要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"SAGE Therapeutics (SAGE) said Wednesday that its phase 2 DIMENSION study of dalzanemdor in participants with cognitive impairment associated with Huntington's Disease did not meet its primary and secondary endpoints.The company said that the study was unable to demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo and as a result, it does not plan further development.Sage Therapeutics' share price fell more than 8% in recent premarket activity on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}